BioVentix PLC Director/PDMR Shareholding
31 Octobre 2024 - 8:00AM
RNS Regulatory News
RNS Number : 3204K
BioVentix PLC
31 October 2024
Bioventix
plc
("Bioventix" or "the
Company")
Director
Dealing
Bioventix plc (BVXP), a UK company
specialising in the development and commercial supply of
high-affinity monoclonal antibodies for applications in clinical
diagnostics, announces that the Company was notified on 30 October
2024 that on 30 October 2024 Bruce Hiscock, Chief Financial Officer
of the Company, purchased a total of 300 ordinary shares of 5 pence
each in the Company ("Ordinary Shares"), at an average price of
3,330 pence per Ordinary Share (the "Purchase").
Following the Purchase, Bruce
Hiscock has a beneficial interest in 1,089 Ordinary Shares,
representing approximately 0.01 per cent. of the issued share
capital of the Company.
The notification below, made in
accordance with the requirements of the EU Market Abuse Regulation,
provides further details.
For
further information please contact:
|
Bioventix plc
Peter Harrison
|
Chief Executive
Officer
|
Tel: 01252 728 001
|
|
|
|
|
|
Cavendish
Geoff Nash / Abigail Kelly
Nigel Birks / Harriet
Ward
|
Corporate Finance
ECM
|
Tel: 020 7220 0500
|
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Bruce Hiscock
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Chief Financial
Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial
notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Bioventix Plc
|
|
b)
|
LEI
|
213800225MHX7LZQY108
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 5 pence
each
|
|
Identification
code
|
GB00B4QVDF07
|
|
b)
|
Nature of the
transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and
volume(s)
|
300 Ordinary
Shares
3,330 pence
|
|
d)
|
Aggregated
information:
· Aggregated
volume
· Price
|
Purchase of 300 Ordinary Shares at
3,330 pence each
|
|
e)
|
Date of the
transaction
|
30 October 2024
|
|
f)
|
Place of the
transaction
|
London Stock Exchange, AIM Market
(XLON)
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHEAAEEDSSLFAA
Bioventix (LSE:BVXP)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Bioventix (LSE:BVXP)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
